Cognex Reports Second Quarter 2025 Results

Core Viewpoint - Cognex Corporation reported a strong financial performance in the second quarter of 2025, highlighting revenue growth, improved margins, and significant cash flow generation, indicating effective execution of strategic priorities and a focus on long-term value creation [2][3][6]. Financial Performance Highlights - Revenue for Q2 2025 was $249 million, a 4% increase from $239 million in Q2 2024, with a 3% increase on a constant-currency basis [3][7]. - Operating income rose to $43 million, up 13% year-over-year, with an operating margin of 17.4%, an increase of 130 basis points from the previous year [3][7]. - Adjusted EBITDA was $52 million, reflecting a 9% increase year-over-year, with an adjusted EBITDA margin of 20.7%, marking the first time it exceeded 20% since Q2 2023 [3][7]. - Net income per diluted share increased to $0.24, a 15% rise from $0.21 in the same quarter last year, while adjusted diluted earnings per share were $0.25, up 12% [3][7]. Balance Sheet and Cash Flow Highlights - As of June 29, 2025, Cognex had $553 million in cash and investments with no debt, indicating a strong financial position [7]. - The company generated $43 million in cash from operating activities, a 54% increase compared to $28 million in Q2 2024, and free cash flow of $40 million, up 74% from $23 million [7]. - The second quarter free cash flow conversion rate was 100% of net income, demonstrating effective cash management [7]. Strategic Initiatives - Cognex announced the launch of OneVision, a cloud platform for AI-powered Machine Vision, aimed at enhancing its product offerings [6]. - The company entered a commercial partnership to better serve OEM customers in medical lab automation, expected to contribute between $8 million and $14 million to revenue in Q3 2025 [9]. Guidance - For Q3 2025, Cognex expects revenue between $245 million and $265 million, representing a 9% increase year-over-year, with an adjusted EBITDA margin forecasted between 19.5% and 22.5% [11].